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Abstract
Background: S. aureus is a coloniser and pathogen of humans and mammals. Whole genome sequences of 58 strains 
of S. aureus in the public domain and data from multi-strain microarrays were compared to assess variation in the 
sequence of proteins known or putatively interacting with host.
Results: These included 24 surface proteins implicated in adhesion (ClfA, ClfB, Cna, Eap, Ebh, EbpS, FnBPA, FnBPB, IsaB, 
IsdA, IsdB, IsdH, SasB, SasC, SasD, SasF, SasG, SasH, SasK, SdrC, SdrD, SdrE, Spa and SraP) and 13 secreted proteins 
implicated in immune response evasion (Coa, Ecb, Efb, Emp, EsaC, EsxA, EssC, FLIPr, FLIPr like, Sbi, SCIN-B, SCIN-C, VWbp) 
located on the stable core genome. Many surface protein genes were missing or truncated, unlike immune evasion 
genes, and several distinct variants were identified. Domain variants were lineage specific. Unrelated lineages often 
possess the same sequence variant domains proving that horizontal transfer and recombination has contributed to 
their evolution. Surprisingly, sequenced strains from four animal S. aureus strains had surface and immune evasion 
proteins remarkably similar to those found in human strains, yet putative targets of these proteins vary substantially 
between different hosts. This suggests these proteins are not essential for virulence. However, the most variant protein 
domains were the putative functional regions and there is biological evidence that variants can be functional, arguing 
they do play a role.
Conclusion: Surface and immune evasion genes are candidates for S. aureus vaccines, and their distribution and 
functionality is key. Vaccines should contain cocktails of antigens representing all variants or they will not protect 
against naturally occurring S. aureus populations.
Background
Staphylococcus aureus is a highly adaptive and versatile
gram-positive bacterium that has major importance to
human and animal health. In humans 20% of a healthy
population are persistently colonised in the anterior nares
of the nose and a further 60% are intermittently colonised
[1]. S. aureus is a common cause of minor skin and
wound infections, but can cause serious and even fatal
infections, particularly in the immunocompromised. The
emergence of methicillin-resistant S. aureus (MRSA)
worldwide is of major concern as this dramatically
reduces the choice of effective antibiotics for prevention
and treatment of a very common infection in both hospi-
tals and communities [2].
S. aureus also colonises a range of mammals, including
companion animals such as dogs, cats and horses, and
livestock such as cows, pigs and goats. It can also colonise
birds such as chickens and turkeys. All of these animal
species can become infected with S. aureus, much like
humans, and S. aureus is a common cause of dairy cow
mastitis with substantial economic impact. Of further
concern is the presence of MRSA strains in a variety of
animals such as cats, dogs, horses, cows, pigs, chickens
and rats [3-7]. These animals may act as important reser-
voirs for human colonisation as is the case for MRSA
sequence type (ST)398 that colonises pigs. Understand-
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factors, and specifically the host- pathogen molecular
interactions, involved in host-to-host transmission and
colonisation is essential for us to expose novel opportuni-
ties for the control of the pathogen. In particular, vaccines
for preventing S. aureus infection in livestock and/or
humans would be useful, but commercial livestock vac-
cines and human clinical trails have so far proved disap-
pointing.
Adherence is an essential step required for bacterial
colonisation of a new host. S. aureus can express a variety
of surface bound proteins (also referred to as microbial
surface components recognising adhesive matrix mole-
cules, or MSCRAMMs) that interact with host extracellu-
lar ligands, such as collagen, fibrinogen (FG), fibronectin
(FN-1), vitronectin (VN), elastin (ELN), prothrombin
(PT) and von Willebrand factor (vWF) [8,9]. In addition,
S. aureus produce a variety of secreted proteins involved
in immune evasion or modulation, often targeting com-
plement and neutrophil recruitment [10-12].
S. aureus populations consist of dominant lineages with
some minor lineages. Multi- strain whole genome S.
aureus microarray studies have shown that each S. aureus
lineage is highly distinct, and that each lineage possesses
a unique combination of conserved surface proteins and
their regulators [13]. Difference also exists in the expres-
sion and secretion of S. aureus proteins [14]. The major
human lineages are clonal complex (CC)1, CC5, CC8,
CC9, CC12, CC15, CC22, CC25, CC30, CC45 and CC51
[15]. The lineages that have acquired mecA to become
widespread hospital acquired (HA-)MRSA are CC5, CC8,
CC22, CC30, CC45 and a hybrid lineage CC239 [16,17].
The lineages that have acquired mecA to become wide-
spread community associated (CA-)MRSA are CC1, CC8,
CC30, CC59 and CC80 [18]. Companion animals are usu-
ally colonised and infected with lineages typically seen in
humans [4]. Cows are colonised and infected with their
own different lineages that are rarely if ever found in
humans, such as CC151, CC771, CC188, CC97, CC130
[14]. In contrast, pigs can be colonised (but are rarely
infected) with CC398, which has acquired mecA, and this
lineage is capable of causing infection in humans [18,19].
Poultry are susceptible to infection with CC5 isolates
[20]. Furthermore, there are known to be wide variations
in the distribution of lineages between different geo-
graphical locations [21,22].
A bounty of new S. aureus genome sequences has
recently been released into the public domain. Our over-
all aim was to investigate genetic variation in S. aureus
core and lineage-specific surface and immune evasion
proteins compared to their cognate host proteins, to bet-
ter identify which are the most likely to be essential dur-
ing colonisation and infection. We compared whole
genome sequences of the first 58 S. aureus genomes from
15 lineages and including 4 animal strains. We also
extend our previous microarray analysis of human and
animals isolates to include human MRSA lineages
CC239, CC59 and CC80, and the pig MRSA clone
CC398. Since our previous study, a number of new adhe-
sion and immune evasion genes have been characterised,
and these are also included in the analysis. Finally, we
compared the known and putative human and animal
protein targets that interact with S. aureus for genetic
variation.
Results
Genes selected for sequence variation analysis fitted one
of three criteria; genes that encode (i) surfaced bound
proteins that possess LPxTG anchoring motifs (ii) pro-
teins known to interact with host extracellular ligands (iii)
secreted proteins that are known to have a role in
immune evasion/modulation [9,23]. Gene sequences are
avilable from a total of a total of 58 S. aureus isolates
(Table 1). 25 genes encoding surface bound proteins
(Additonal file 1 Table S1) and 13 secreted proteins
(Additonal file 2 Table S2) were analysed for sequence
variation. Abbreviations of S. aureus and host genes and
proteins are shown in tables 2 and 3.
Sequence variation in surface bound S. aureus proteins
Eight (ebpS, fnbpA, isaB, isdA, isdH, sasF, sasH and spa)
of the 25 genes that encode these surface bound proteins
were present in all sequenced S. aureus genomes. Some of
the remaining 16 genes were absent from a small number
of S. aureus genomes (clfA, clfB, eap, ebh, fnbpB, isdB,
sasB, sasC, sasD, sasG, sdrC, sdrD and sraP) whilst others
were absent from the majority of S. aureus genomes (cna,
sasK and sdrE) (Additonal file 1 Table S1). This indicates
that many surface bound proteins are not essential for
survival and replication of S. aureus. Many of these pro-
teins are known to adhere to the same host ligand and
redundancy in S. aureus adhesins is common.
Variation was identified in all 25 surface bound proteins
indicating that surface adhesins are not only present/
absent, but also variable amongst S. aureus genomes.
Variation between lineages was higher than within lin-
eages for all genes (Additonal file 1 Table S1). The protein
domains at the host-interface had a higher level of inter-
lineage variation in comparison to other protein domains
for 12 S. aureus surface bound proteins (Aaa, ClfA, ClfB,
Eap, EbpS, FnBPA, FnBPB, SasG, SdrC, SdrD, SdrE and
Spa) (Additonal file 1 Table S1). The iron-regulated sur-
face adhesins (IsdA, IsdB and IsdH), Cna, SasB and SraP
have lower levels of interlineage variation present in puta-
tive host-interface domains than other protein domains.
Knowledge of protein domains in the remaining 6 pro-
teins is not currently available; nonetheless there are
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Lineage Strain Host Status GenBank Accession number Published reference
CC ST
1 1 MSSA476* H I BX571857 [48]
1 MW2* H I BA000033 [49]
1 TCH70 H S NZ_ACHH00000000 http://www.ncbi.nlm.nih.gov
5 5 A5937 H I NZ_ACKC00000000 http://www.broadinstitute.org/
5 A6224 H I NZ_ACKE00000000 http://www.broadinstitute.org/
5 A6300 H I NZ_ACKF00000000 http://www.broadinstitute.org/
5 A8115 H S NZ_ACKG00000000 http://www.broadinstitute.org/
5 A8117 H S NZ_ACYO00000000 http://www.broadinstitute.org/
5 A9719 H U NZ_ACKJ00000000 http://www.broadinstitute.org/
5 A9763 H U NZ_ACKK00000000 http://www.broadinstitute.org/
5 A9781 H U NZ_ACKL00000000 http://www.broadinstitute.org/
5 A9299 H U NZ_ACKH00000000 http://www.broadinstitute.org/
5 A10102 H U NZ_ACSO00000000 http://www.broadinstitute.org/
5 CF-Marseille H I NZ_CABA00000000 [50]
5 ED98* A I CP001781 [20]
5 Mu3* H I AP009324 [51]
5 Mu50* H I BA000017 [52]
5 N315* H S BA000018 [52]
105 JH1* H I CP000736 [53]
105 JH9* H I CP000703 [53]
7 7 USA300 TCH959* H S NZ_AASB00000000 http://www.ncbi.nlm.nih.gov
8 8 A5948 H U NZ_ACKD00000000 http://www.broadinstitute.org/
8 A9765 H U NZ_ACSN00000000 http://www.broadinstitute.org/
8 NCTC 8325* H S CP000253 [54]
8 Newman* H I AP009351 [55]
8 USA300 FPR3757* H I CP000255 [56]
8 USA300 TCH1516* H S CP000730 [57]
250 COL* H S? CP000046 [58]
10 10 H19 H U NZ_ACSS00000000 http://www.broadinstitute.org/
145 D139 H U NZ_ACSR00000000 http://www.broadinstitute.org/
22 22 EMRSA15/5096* H I http://www.sanger.ac.uk/pathogens
30 30 55/2053 H U NZ_ACJR00000000 http://www.broadinstitute.org/
30 58-424 H U NZ_ACUT00000000 http://www.broadinstitute.org/
30 65-1322 H U NZ_ACJS00000000 http://www.broadinstitute.org/
30 68-397 H U NZ_ACJT00000000 http://www.broadinstitute.org/
30 A017934/97 H U NZ_ACYP00000000 http://www.broadinstitute.org/
30 Btn1260 H U NZ_ACUU00000000 http://www.broadinstitute.org/
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IsaB, SasC and SasF, in comparison to the C terminus.
Intralineage amino acid variation is present in all sur-
face bound proteins. Low levels of variation (proportion
of variable sites < 0.05) exist in 22 surface proteins, whilst
SdrD, Spa and SraP have higher levels of intralineage vari-
ation. Across all proteins there are small levels of intralin-
eage variation in host-interface domains (proportions of
variable amino acid sites vary from 0.000 to 0.078) (Addi-
tonal file 1 Table S1). Interestingly, intralineage levels of
variation differ between lineages in host-interface
domains of a small subset of surface bound proteins. For
example, the FN-1 binding domain of FnBPA has a pro-
portion of variable amino acid sites of 0.032, 0.016 and
0.008 for CC5, CC8 and CC30 respectively, whilst there is
an interlineage variation of 0.139. Such variation could
support S. aureus lineage adaption to hosts and environ-
ments, and/or S. aureus evasion of the host immune
response.
An example of a highly variable surface protein is
FnBPA. The distribution of protein domain variants of
FnBPA across CC lineages shows evidence of recombina-
tion. (Additonal file 3 Table S3). For the purposes of this
paper we define a domain variant as any domain with a
sequence encoding one amino acid difference. In addi-
tion, we define a domain that has greater than 5% of vari-
able amino acids as a major variant within a domain. The
data shows that a range of major and/or minor sequence
30 C101 H U NZ_ACSP00000000 http://www.broadinstitute.org/
30 E1410 H U NZ_ACJU00000000 http://www.broadinstitute.org/
30 M1015 H U NZ_ACST00000000 http://www.broadinstitute.org/
30 M876 H U NZ_ACJV00000000 http://www.broadinstitute.org/
30 M899 H U NZ_ACSU00000000 http://www.broadinstitute.org/
30 MN8 H S NZ_ACJA00000000 http://www.ncbi.nlm.nih.gov
30 TCH60 H S NZ_ACHC00000000 http://www.ncbi.nlm.nih.gov
30 WBG10049 H V NZ_ACSV00000000 http://www.broadinstitute.org/
30 WW2703/97 H U NZ_ACSW00000000 http://www.broadinstitute.org/
34 C160 H U NZ_ACUV00000000 http://www.broadinstitute.org/
36 MRSA252* H I BX571856 [48]
42 42 C427 H U NZ_ACSQ00000000 http://www.broadinstitute.org/
45 45 A9635 H U NZ_ACKI00000000 http://www.broadinstitute.org/
72 72 TCH130 H S NZ_ACHD00000000 http://www.ncbi.nlm.nih.gov
151 151 RF122/ET3-1* B I AJ938182 [59]
239 239 JKD6008 H I NZ_ABRZ00000000 http://www.ncbi.nlm.nih.gov
239 JKD6009 H I NZ_ABSA00000000 http://www.ncbi.nlm.nih.gov
239 0582/TW20* H I FN433596 http://www.sanger.ac.uk/pathogens
398 398 S0385 * P/H I AM990992 http://www.ncbi.nlm.nih.gov
425 425 LGA251* B I http://www.sanger.ac.uk/pathogens
431 431 M809 H U NZ_ACUS00000000 http://www.broadinstitute.org/
58 S. aureus genomes have been sequenced to date from14 different clonal complex lineages (CC). CC5, CC8 and CC30 are the most extensively 
sequenced with17, 8 and17 genomes currently available. Sequence type (ST) of each strain is shown, and strains with fully annotated genomes 
are denoted with an (*). Host origin of the strain is denoted as avian (A), bovine (B), human (H) and porcine (P). Infection status of the strain is 
shown as a strain isolated from an infection (I), a strain isolated from another source (S) or a strain for which the origin is publically unavailable 
(U). GenBank accession numbers are shown where possible, as well as published references or corresponding websites.
Table 1: Sequenced Staphylococcus aureus genomes (Continued)
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Protein name Gene symbol Protein symbol Published reference
Autolysin/adhesin from S. aureus aaa Aaa [60]
Clumping factor A clfA ClfA [61-63]
Clumping factor B clfB ClfB [64,65]
Chemotaxis inhibitory protein of Staphylococcus aureus chp CHIP [39]
Collagen adhesin cna Cna [66-68]
Coagulase coa Coa [69,70]
Extracellular adhesion protein eap Eap [71-73]
ECM-binding protein homologue ebh Ebh [74-77]
Elastin-binding protein of Staphylococcus aureus ebps EbpS [78-80]
Extracellular complement-binding protein ecb Ecb [11]
Extracellular fibrinogen-binding protein efb Efb [81-83]
Extracellular matrix protein emp Emp [84]
ESAT-6 secretion accessory C esaC EsaC [85,86]
ESAT-6 like factor A esxA EsxA [86]
ESAT-6 secretion system C essC EssC [86]
FPR-like1 inhibitory protein fll FLIPr [10]
FPR-like1 inhibitory protein like flr FLIPr-like [11]
Factor which affects the methicillin resistance level and autolysis in 
the presence of Triton X-100 B
fmtB FmtB [24,87]
Fibronectin binding protein A fnbpA FnBPA [24,88-93]
Fibronectin binding protein B fnbpB FnBPB [89]
Immunodominant surface antigen B isaB IsaB [94]
Iron-regulated surface determinants A isdA IsdA [9,95-97]
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Page 6 of 15variations exist for the N terminus of the variable region
domain, the fibrinogen (FG) and elastin (ELN) binding
domain and the fibronectin (FN-1) binding domain
(Additonal file 3 Table S3). Within each CC lineage only
one major sequence variant exists for each FnBPA
domain, and therefore the whole gene is lineage-specific.
Surprisingly, the same major sequence variant of a
domain is often found in unrelated lineages. Further-
more, whilst a lineage may share a major sequence vari-
ant of one domain with one unrelated lineage, it may
share a major sequence variant at an adjacent domain
with a different unrelated lineage. This shows that the
fnbpA gene has a mosaic structure and indicates the
fnbpA locus is evolving through recombination, in addi-
Iron-regulated surface determinants B isdB IsdB [9,96]
Iron-regulated surface determinants H isdH IsdH [9,97,98]
Penicillin-binding protein 2a conferring resistance to methicillin mecA MecA
Staphylokinase sak SAK [39]
Staphylococcus aureus protein B sasB SasB [87]
Staphylococcus aureus protein C sasC SasC [23,99]
Staphylococcus aureus protein D sasD SasD [22]
Staphylococcus aureus protein F sasF SasF [22,100]
Staphylococcus aureus protein G sasG SasG [22,101,102]
Staphylococcus aureus protein H sasH SasH [22,103]
Staphylococcus aureus protein K sasK SasK [22]
Staphylococcus aureus binder of IgG sbi Sbi [12,104,105]
Staphylococcal complement inhibitor scn SCIN [39]
Staphylococcal complement inhibitor B scin-B SCIN-B [11]
Staphylococcal complement inhibitor C scin-C SCIN-C [11]
Serine aspartate repeat protein C sdrC SdrC [106,107]
Serine aspartate repeat protein D sdrD SdrD [106-109]
Serine aspartate repeat protein E sdrE SdrE [106]
Staphylococcus aureus protein A spa Spa [110-112]
Serine-rich adhesin for platlets sraP SraP [113,114]
von Willebrand factor-binding protein vwb VWbp [115-117]
Table 2: Abbreviation list of Staphylococcus aureus genes/proteins (Continued)
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Page 7 of 15tion to point mutation. Loughman et al. [24] have previ-
ously identified FnBPA sequence variants from human
strains of lineages that have not had their genome
sequenced (CC12, CC15, CC25, CC55, CC59, CC101,
CC121 and CC509) and classified seven isotypes. They
have shown that all isotypes have human fibrinogen bind-
ing activity, but that isotype I (found in CC8, CC15 and
CC55) binds weakly to elastin. Inclusion of these partial
gene sequences [GenBank: AM749006-15], correspond-
ing to amino acid residues 1- 565, in our analysis suggests
these gene variants are typical. Interestingly, they prove
that no animal S. aureus strain has a major domain vari-
ant that is not found in a human S. aureus lineage. The
bovine strain LGA25 1 (CC425) shares a major variant of
the FG and ELN binding domain with human strains
TCH959 (CC7) and 3110 (CC 12). Likewise, bovine strain
RF122 (CC151) has a major variant of the FG and ELN
binding domain that is also found in strains D139 and
H19 (both CC10). Porcine strain S0385 (CC398) shares a
major variant of the FG and ELN binding domain with
human strain 3153 (CC509), varying at only 11 amino
acid residues. The N terminus of the variable region of
these three strains is a recombination of sequences found
in a range of human S. aureus lineages. This indicates that
animal S. aureus lineages have domain variants also
found in human S aureus lineages.
Interestingly, animal lineages possess a unique combi-
nation of FnBPA domain variants that are not found in
human lineages (Additonal file 3 Table S3). A unique
combination of domain variants is also found in animal
isolates in other surface bound proteins (ClfA, Eap, Ebh,
EbpS, IsdB, SdrD and SdrE). In addition, novel domain
variants are found in animal lineages in other surface
bound proteins (FnBPB, IsdA, IsdH and SasB). Interest-
ingly, much of this novel domain variation has been gen-
erated by intradomain recombination events. These
proteins could be important in the adaptation of S. aureus
to different host species. Determining whether animal
lineages truly have a unique domain variant or possess a
unique combination of domain variants can only truly be
resolved by future sequencing of other major human S.
aureus lineages, or through future microarray studies. For
other surface proteins, animal lineages do not have a
unique combination of domain variants, and neither do
they possess unique domain variants (Aaa, ClfB, Cna,
IsaB, SasC, SasF, SasG, SasH, SasK, SdrC, Spa and SraP).
This therefore questions the importance of these genes in
the adaptation of S. aureus lineages to different host spe-
cies.
Sequence variation in secreted S. aureus proteins
The sequence variation of 13 secreted S. aureus genes
encoding proteins that have characterised or hypothe-
sised roles in immune evasion was analysed (Additonal
file 2 Table S2). Eight (coa, ecb, efb, emp, esxA, essC, sbi
and vwbp) of the 13 secreted genes are present in all
sequenced S. aureus genomes. In addition, each genome
either possesses a gene encoding FLIPr or FLIPr-like and
SCIN-B or SCIN-C suggesting that the function of these
homologs is essential to S. aureus survival and replication
(Additonal file 2 Table S2). As functions of all these pro-
teins, except EsaC, are present in all sequenced genome
this suggests that secreted proteins involved in immune
evasion are critical to S. aureus.
All 13 secreted proteins are variable amongst S. aureus
genomes (Additonal file 2 Table S2). There is a higher
level of interlineage variation in host interface domains
than other domains for Coa and vWbp. In Efb there is
greater variation in the signal sequence than domain
characterised in host interactions. Sbi has a characterised
host- interface domain, yet there is more variation in the
C terminus (proportion of variable residues = 0.25 1) than
the Ig or C3 binding domains (proportion of variable res-
idues ranges from 0.000 to 0.125). Functional domains are
currently unidentified for Ecb, Emp, EsaC, EsxA, EssC,
FLIPr, FLIPr-like, SCIN-B and SCIN-C.
Intralineage variation is present in Coa, Efb, Emp, EssC,
FLIPr, Sbi and VWbp at low levels (proportion of variable
sites < 0.0 19) and absent in the remaining proteins. The
exception is FLIPr-like which is more variable and fre-
quently truncated. The level of and location of intralin-
eage variation differs between the CC5, CC8 and CC30
lineages. The secreted proteins involved in immune eva-
sion of S. aureus lineages may be differentially adapted,
but that there was little adaptation of strains within lin-
eages.
An example of a highly variable immune evasion gene,
coa or coagulase, is shown in more detail in additonal file
4 Table S4. There are a variety of conserved domains
spread amongst the lineages. Similarly to FnBPA, unre-
lated lineages often share the same domain variants
(Additonal file 4 Table S4). However, there is less evi-
dence of recombination within the coa gene than within
the fnbpA gene as there are fewer examples of unrelated
lineages sharing the same sequence variant. An exception
to this is the C terminus. The pig CC398 coa gene is
highly similar to the human CC45 coa gene. The avian
CC5 strain has the same gene as the human CC5. The
bovine CC425 is similar to human CC5 genes but has a
different central region, while the bovine CC151 strain
has a unique coa gene.
Animal lineages possess unique combinations of Coa
domain variants that are not found in human lineages,
similar to FnBPA (Additonal file 4 Table S4). Animal lin-
eages also have a unique combination of domain variants
for other secreted proteins (Emp and VwBP). Animal lin-
eages possess unique domain variants in EssC, SCIN-B
and VwBP, whilst for other secreted proteins (Ecb, Efb,
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http://www.biomedcentral.com/1471-2180/10/173
Page 8 of 15EsaC, EsxA, FLIPr, FLIPr-like, SCIN-C and Sbi) animal
lineages do not have unique domain variants or a unique
combination of domain variants.
Microarray data
Microarray data is useful for confirming the distribution
of genes amongst large populations, for showing that lin-
eages are conserved, and investigating unsequenced lin-
eages. Using the seven-strain S. aureus microarray the
400 isolates, representing MSSA, HA-MRSA, CA MRSA
and from human, bovine, equine, pig, goat, sheep and
camel, clustered into 20 dominant lineages. The distribu-
tion of surface and secreted gene variants is shown in Fig.
1, and confirms that all strains of a lineage usually carry
the same distribution of surface and immune evasion
genes and variants, and that variants are often distributed
across unrelated lineages. The distribution of genes with
poorly performing spots (eap, ebpS, emp, esaC, scin-c and
vwbp) and genes with spots that do not discriminate lin-
eage-specific variation (clfA, clfB, ecb, efb, EsxA, essC,
isdA, isdB, isdC, isdH, sasB, sasF, sasH, sasK, sbi, sdrC,
spa and sraP) are not reported in this microarray study.
Some gene variants are not included in the microarray
design as they were not identified in the first seven S.
aureus whole genome sequencing projects [25].
Variation in host ligands of S. aureus proteins
The location of and proportion of amino acid variable
sites for human ligands are shown in Table 4. Variation is
present in each of the ligands analysed. Notably, the pro-
portion of variable residues is high (>0.0 15) in the β-
chain (FGB) and γ-chain (FGG) of fibrinogen, and in elas-
tin (ELN). Lower levels of variation exist in the α-chain
(FGA) of fibrinogen (0.0 10), promthrombin (PT) (0.006),
vitronectin (VN) (0.006), fibronectin (FN-1) (0.006) and
the von Willebrand factor (vWF) (0.008). This analysis
shows that the amino acid sequence in S. aureus ligands
varies in humans, and some of this variation is in domains
interacting with ClfA, ClfB and FnBPA. This could pro-
vide a selective pressure for the evolution and adaptation
of S. aureus adhesins in human populations.
The interspecies similarity of host ligands was calcu-
lated for FGB, FGG, FN-1, PT and vWF (Additonal file 5
Tables S5-S9). Species included in analysis are those for
which full sequence is available and annotated. For FGA,
ELN and VTN there was too much variation amongst
interspecies sequences to construct a reliable alignment.
Interspecies similarity matrices are therefore not
reported for these ligands. For fibrinogen the analysis
shows that considerable variation exists in both FGB and
FGG between humans and other animal species that
become colonised with S. aureus, such as dog, cow and
horse (Additonal file 5 Tables S5 and S6). Interestingly,
FGB (similarity = 79.1%) has a lower similarity score for
human and cow homologs than FGG (similarity = 83.7%)
revealing that levels of interspecies variation differ
between chains of complexes for this species pair. Sur-
prisingly, the animal species that has the lowest identity
to human sequence varies amongst the ligands. For
example, the similarity of human vWF to that of pig and
cow is 0.559 and 0.810 respectively, whilst the similarity
of human PT to that of pig and cow is 0.828 and 0.812
respectively (Additonal file 5 Tables S8 and S9). This
analysis shows that there is a substantial interspecies vari-
Table 3: Abbreviation list of host genes/proteins used in 
the manuscript
Protein name Gene symbol Protein 
symbol
Complement protein 3 C3
C3 convertase C4b2a
Collagen type1 CN-1
Cytokeratin10 CK10
Elastin emn ELN
Fibirogen fga, fgb, fgg FGA, FGB, FGG
Fibronectin fn-1 FN-1
Formyl peptide 
receptor
FPR
FPR-Like-1 FPRL1
Haemoglobin Hb
Haptoglobin Hp
Immunogblubin G IgG
Tumour necrosis factor 
receptor1
TNRF1
Thrombospondin1 TSP-1
Vitronectin vtn VN
Prothrombin pt PT
Von Willebrand factor vwf vWF
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Page 9 of 15ation in host ligands that consequently will provide a
selective pressure for the adaptation of S. aureus
adhesins.
Discussion
The multitude of sequencing projects available in the last
year has confirmed previous observations about S. aureus
population structure but also revealed some new sur-
prises. In this manuscript we have focussed specifically
on those proteins that are predicted to interact with host
because of their importance in vaccine development, but
also because they are presumed to define the host-patho-
gen interaction.
Our analysis proves that variation in genes encoding
surface proteins is lineage specific, but that many domain
variants are conserved across unrelated lineages. Most of
the variation occurs in predicted functional domains.
Many are missing in some lineages, or are frequently
truncated. Similarly, the genes encoding secreted pro-
teins predicted to interact with host immune responses
also show variation that is lineage specific, conserved
across unrelated lineages, and occurs in predicted func-
tional domains. The amount of variation in immune eva-
sion genes is less than in the surface proteins, and missing
or truncated proteins are less common.
The surface proteins are major targets for vaccine
development. Vaccines to ClfA, ClfB, FnBPA, IsdA, IsdB,
SdrD, SdrE, Eap, Emp have shown protection in animal
models as have capsule and haemolysin A [26-32]. The
animal model work typically involves vaccinating against
one surface protein variant, and then exposing the ani-
mals to a challenge strain expressing the same surface
protein variant. Human trials of capsule vaccines to pre-
vent infection or colonisation have been disappointing
[33,34]. A trial of a vaccine to enhance ClfA antibody pro-
duced sera that did not protect low birth-weight babies
from sepsis [35]. Furthermore, commercial vaccines for
livestock are generally not effective [36]. Yet, S. aureus
surface proteins are currently in human vaccine trials.
Humans are exposed to a variety of S. aureus lineages.
This paper clearly shows that S. aureus populations carry
a range of unique variants of surface proteins. Therefore,
animals in vaccine trials should be challenged with a
range of S. aureus lineages so that the vaccine is tested
with a representative range of S. aureus surface proteins.
If the vaccine is protective against a range of strains, it
may then be suitable for human trials. Vaccines cocktails
of multiple surface proteins have been tested in animals
[27]. However, these also use the variants found in only
one laboratory lineage. To obtain good coverage, multiple
variants of multiple targets in the vaccine cocktail will
likely be more effective. The lack of variant antigens in
the vaccines currently tested in animals, humans and live-
stock may explain their failure to protect from infection
with naturally occurring S. aureus populations in the
non-laboratory environment.
We note that MRSA strains in our collection typically
had the same surface and secreted protein profiles as
methicillin-sensitive Staphylococcus aureus (MSSA) from
the same lineage. We did not find a surface or secreted
immune marker of MRSA, nor of HA-MRSA or CA-
MRSA strains.
If a surface protein is dispensable in some lineages that
are still able to cause disease, then its role in virulence is
called into question. Many surface proteins appear to
bind multiple host proteins, and multiple surface proteins
may bind the same host protein [9]. Therefore, the role of
individual proteins in disease is difficult to prove and it
seems likely that a combination of proteins is essential for
virulence. Intriguingly, some lineages are thought to be
more associated with particular human hosts than others
[37]. We can show there are subtle variations in the
genetic sequences of human host proteins, especially in
binding regions, which may be implicated in this host
specificity.
Unexpectedly, the sequences of the animal lineages of S.
aureus do not support this hypothesis. If animal strains of
S. aureus interact with animal host proteins the bacteria
would be expected to have animal specific binding pro-
teins or domains. However this is generally not the case,
and the animal strains show gene sequences remarkably
similar to those found in human strains. No unique sur-
face proteins with an LPxTG anchoring domain could be
identified in any of the animal sequencing projects [38].
Yet, the sequence of predicted animal protein targets is
substantially different from human counterparts. How do
S. aureus strains interact specifically with non-human
hosts? The importance of individual proteins in host-
pathogen interactions is therefore difficult to confirm.
One factor that is not taken into account in this study is
the possibility of strains acquiring additional genes on
mobile genetic elements (MGEs). Indeed, we have previ-
ously shown that a bacteriophage of the phi3 family is
found in most human isolates of S. aureus but in only
about 20% of animal strains [14]. This phage frequently
carries genes encoding human specific immune evasion
proteins chemotaxis inhibitory protein (chip), staphylo-
coccal complement inhibitor (scin, (unique from scin-B
and scin-C) and staphylokinase (sak) [39]. Our analysis of
the animal S. aureus strain genome sequences did not
identify any novel MGE genes with a possible surface or
immune evasion function. Although it is true that novel
immune evasion genes can be difficult to identify from
sequence alone, and some may be characterised in the
future. The distribution of these genes among large popu-
lations awaits large scale comparative genomics studies
using sequencing or extended microarray platforms.
The fact that surface and immune evasion proteins var-
ied predominantly in predicted functional regions sug-
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Page 10 of 15gests these proteins do play a role in host interaction and
that variants have been selected for. Loughman et al. [24]
have investigated seven variants (isotypes) of the FnBPA
protein for their ability to bind human fibrinogen and
elastin. All variants bound fibrinogen equally well, but
one variant bound elastin less efficiently. The fact that all
the variants had activity supports the idea that FnBPA
does indeed play a role in host-pathogen interaction as
presumably variants that do not bind are not selected for.
But it is also interesting that elastin binding could be dis-
pensable. Jongerius et al. [11] have shown that SCIN-B
and SCIN-C are unable to inhibit AP-mediated hemolysis
in serum of species other than humans. They also showed
that Ecb and Efb blocked complement of human and 7
other species. Therefore, the function of all variants
against all hosts cannot be assumed until appropriate bio-
logical studies are performed.
Although human and animal lineages have been well
described, some human strains do cause infection in ani-
mals and vice versa [4,12,40]. If specific host-pathogen
interactions are necessary, then perhaps each strain car-
ries one or more key surface and immune evasion pro-
teins that are specific to each of the animal species they
colonise. Alternatively, some bacterial proteins may inter-
act with a broad host range. Biological studies to investi-
gate these hypotheses across a broad range of surface and
immune evasion proteins are needed.
While 58 genomes are currently available for analysis,
there are still many lineages of S. aureus that have not
been sequenced. This is likely to change in the next few
years. However, our analysis suggests that the majority of
genes on the stable core and lineage specific regions of
the genome may have been sequenced already, and few
very different genes or gene variants will be described.
The exceptions may be in fnbpA and coa which seem to
be remarkably variable and frequently recombining. Sin-
gle nucleotide polymorphisms and variable repeat
regions in genes (Additonal file Table S1 and additional 2
Table S2) are also expected to continue to evolve and
vary. New genomes may reveal new surprises, and often
identify new MGEs [41].
Conclusions
In summary, the similarity of surface and immune eva-
sion genes in S. aureus strains from different animal hosts
with very different target proteins is surprising and sug-
gests specific host-pathogen interactions via these pro-
teins are not essential for virulence. However, variation in
S. aureus proteins is predominantly in predicted func-
tional regions and there is some biological evidence that
Figure 1 Microarray analysis. Microarrays show gene variants are conserved across unrelated lineages. Genes are listed in order by name and by 
their annotated gene number prefixed with the strain that was used as the template for the PCR probe on the microarray (R, MRSA252; N, N315; 8, 
8325; M, MW2; U, Mu50). A black box indicates the gene or gene variant is present in that lineage. '*' indicates the genome of a strain from this lineage 
has been sequenced. '+' indicates ORFs from this lineage are included on the 7 strain microarray. C indicates community associated MRSA were in-
cluded, and H indicates hospital associated MRSA were included. Strains from the following hosts were included: h, human, b, bovine, e, equine, p, 
pig. 'v' denotes a PCR product designed to a specific variant region. 'u' indicates variation in gene distribution for that lineage.
Gene Identifier 
1
*+
5
*+
8
*+
12 15 22 
*
Lineage
151
*
188 239
*
398
*
771 873 25 30
*+
45 51 59 80 97 130
MRSA  C H CH   H  H H  C C       CH  
Host  hbe h hbe h h he h h h h h h hb hb b hb h hp b b 
cna  R-2274     
fnbpA R-2580v                   
fnbpA N-2291v         
fnbpA 8-3446                             
fnbpB N-2290v                                   
fnbpB 8-3444                                 
isaB R-2717           
sasC R-1841   u              
sasD R-0136 
sasG N-2285                   
sdrD N-0519v                       
sdrE N-0520v 
coa N-0222v    u                               
coa M-0206v          
coa R-0222v     
coa 8-0239v                                 
flipr N-1001  u  u 
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This argues that specific host-pathogen interactions of
these proteins are essential for virulence. This is an area
of research that requires further investigation. Impor-
tantly, vaccine development should utilise information on
the variation, distribution and function of surface protein
antigens amongst lineages to ensure that cocktails of gene
variants are included. Otherwise vaccines may fail in
human trials, and/or encourage selection of lineages dif-
ferent to those of laboratory strains, including CA-
MRSA.
Methods
Staphylococcus aureus genomes
Sequence data is available for the genomes of 58 Staphy-
lococcus aureus isolates on the GenBank database http://
www.ncbi.nlm.nih.gov and the Broad Institute website
http://www.broadinstitute.org/. The source and accession
numbers of these genomes is shown in table 1. The
genetic sequence of an additional 3 S. aureus genomes
was made available by Matt Holden (EMRSA-15 and
LGA251; Sanger Centre, UK) and Ad Fluit (S0385; Uni-
versity Medical Centre Utrecht, Netherlands). Strains are
of human origin except strain RF122 which is a bovine
mastitis isolate, strain LGA25 1 from a bovine infection,
strain ED98 from a diseased broiler chicken, and strain
ST398 isolated from a human but likely from pig origin.
Sequence analysis was therefore performed on the
genomes of 58 S. aureus isolates that represent 18 differ-
ent multi locus sequence types (MLST) (ST1, ST5, ST7,
ST8, ST22, ST30, ST34, ST36, ST42, ST45, ST72, ST105,
ST145, ST151, ST239, ST250, ST398, ST425 and ST431)
and 15 different clonal complex (CC) lineages (CC1, CC5,
CC7, CC8, CC10, CC22, CC30, CC42, CC45, CC72,
CC151, CC239, CC398, CC425 and CC431) (Table 1). It
should be noted that some of the genomes are not com-
plete, and some may have minor errors that lead to the
overestimation of truncated proteins.
Sequence analysis of Staphylococcus aureus genes
The sequence of each gene in a genome was first identi-
fied using the BLAST function of the GenBank database
http://www.ncbi.nlm.nih.gov/blast. Sequences of a gene
were subsequently aligned using the ClustalW program
and then edited by hand if necessary in BioEdit [42,43].
Domains of S. aureus proteins were identified using the
UniProt resource of protein sequence and function http:/
/www.uniprot.org and/or from previous literature. In
cases where the domains of a protein have not previously
been characterised, the signal sequence was identified
using SignalP 3.0 and the remaining sequence was split
into an N-terminus and C- terminus [44].
The proportion of variable sites in each protein domain
was calculated between all sequences available for each S.
aureus gene, and is denoted as interlineage variation. The
proportion of variable sites within protein domains was
Table 4: Variation in human proteins
Ligand Gene NCBIGeneID Variable amino acid sites Proportion of 
variable sites
Characterised interacting
S. aureus protein(s)
Elastin eln 2006 40, 71,165, 298, 311, 398, 422, 
463, 494, 503, 544, 581, 651, 711
0.019 EbpS, FnBPA
Fibrinogen/Fibrin fga 2243 6, 331b, 392, 446, 456, 507, 729 0.010 ClfB, FnBPB, Ebh, IsdA,
fgb 2244 2, 86,100,170,192, 265, 398, 478 0.016 Efb,
fgg 2266 12,14, 25, 54, 77, 87, 
89,113,114,132,140,177,191, 
219, 410ac
0.033 ClfA, FnBPA
Fibronectin fn-1 2335 15, 251c, 352, 759, 817, 
984,1044,1103,1558, 2195, 2212, 
2261, 2275, 2281
0.006 FnBPA, FnBPB,
Prothrombin f2 2147 165, 200, 272, 386 0.006 VWbp
Vitronectin vtn 7448 122, 268, 400 0.006 Unknown protein [118]
von Willebrand 
factor
vwf 7450 137, 318, 325d, 471, 484, 653, 
740, 817, 852, 
885,1380,1381,1435,1472,1565,
1569, 2126, 2178, 2281, 2342, 
2561, 2705
0.008 VWbp Spa
a residues located in ClfA binding region [61].
b residues located in ClfB binding region [64].
c residues located in FnBPA binding region [91,92].
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CC30, as these lineages had genome sequence available
from multiple isolates (17, 7 and 18 isolates respectively).
Within these CC lineages the extent of intralineage varia-
tion was calculated for ST5, ST8 and ST30, respectively.
The extent of interlineage and intralineage variation in S.
aureus proteins involved in adherence and nasal colonisa-
tion and/or immune modulation can therefore be com-
pared.
Microarray analysis
A total of 400 S. aureus isolates were analysed represent-
ing MSSA, HA-MRSA, CA MRSA and from human,
bovine, equine, pig, goat, sheep and camel. The microar-
ray used in this study was developed and comprehen-
sively described previously [12,23]. Data from previous
studies and additional strains from St George's Hospital
Trust and kindly donated by Mark Enright are included
[12,14,40,45-47].
Sequence analysis of host ligand genes
The sequence of the human genes encoding fibrinogen
(FG), fibronectin (FN), elastin (ELN), vitronectin (VN),
prothrombin (PT) and von Willebrand factor (vWF) were
isolated from the GenBank database, accession numbers
are shown in Additonal file 3 Tables S3. Variable sites of
each ligand were identified from the GenBank SNP
resource http://www.ncbi.nlm.nih.gov/SNP and the pro-
portion of variable sites was calculated.
The sequence of animal genes encoding fibrinogen
(FG), fibronectin (FN-1) prothrombin (PT) and von
Willebrand factor (vWF) were identified by BLAST
search with human gene sequences and aligned in Clust-
alW program and then edited by hand if necessary in Bio-
Edit [42,43]. GenBank accession numbers are shown in
Additonal file 5 Tables S5-S9. A similarity matrix of
sequences was calculated in BioEdit.
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